Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Immunohistochemistry and Scoring
2.3. Statistical Analysis
2.4. Web Server Survival Analysis
3. Results
3.1. Exploring the Correlation and Clinical Significance of HIF-1α, MTDH, IL-10, CCL12, CCL2, VEGF, MMP2, LOX, and CXCR4 Expression in Breast Cancer
3.2. MTDH, and IL-10 Protein Expression Are Positively Correlated with Hormone Receptor Protein Expression
3.3. Expression of MTDH and IL-10 Protein Are Associated with Poor Prognosis of Breast Cancer
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [PubMed]
- Hammond, M.E.H.; Hayes, D.F.; Wolff, A.C.; Mangu, P.B.; Temin, S. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010, 134, e48–e72. [Google Scholar]
- Polyak, K. Heterogeneity in breast cancer. J. Clin. Investig. 2011, 121, 3786–3788. [Google Scholar] [CrossRef]
- Wolff, A.C.; Hammond, M.E.H.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.S.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 2014, 138, 241–256. [Google Scholar] [CrossRef]
- Al Tameemi, W.; Dale, T.P.; Al-Jumaily, R.M.K.; Forsyth, N.R. Hypoxia-modified cancer cell metabolism. Front. Cell Dev. Biol. 2019, 7, 4. [Google Scholar] [CrossRef]
- Walmsley, S.; Harris, A.; Thompson, A.A.R.; Whyte, M.K.B. HIF-mediated innate immune responses: Cell signaling and therapeutic implications. Hypoxia 2014, 2, 47. [Google Scholar] [CrossRef]
- Zhu, G.; Peng, F.; Gong, W.; She, L.; Wei, M.; Tan, H.; Chen, C.; Zhang, D.; Li, G.; Huang, D.; et al. Hypoxia promotes migration/invasion and glycolysis in head and neck squamous cell carcinoma via an HIF-1α-MTDH loop. Oncol. Rep. 2017, 38, 2893–2900. [Google Scholar] [CrossRef]
- Wang, T.; Liu, H.; Lian, G.; Zhang, S.Y.; Wang, X.; Jiang, C. HIF1 α-induced glycolysis metabolism is essential to the activation of inflammatory macrophages. Mediat. Inflamm. 2017, 2017, 9029327. [Google Scholar] [CrossRef]
- Triner, D.; Shah, Y.M. Hypoxia-inducible factors: A central link between inflammation and cancer. J. Clin. Invest. 2016, 126, 3689–3698. [Google Scholar] [CrossRef]
- Krzywinska, E.; Stockmann, C. Hypoxia, metabolism and immune cell function. Biomedicines 2018, 6, 56. [Google Scholar] [CrossRef]
- Liu, W.; Shen, S.M.; Zhao, X.Y.; Chen, G.Q. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int. J. Biochem. Mol. Biol. 2012, 3, 165–178. [Google Scholar] [PubMed]
- Yang, L.; Tian, Y.; Leong, W.S.; Song, H.; Yang, W.; Wang, M.; Wang, X.; Kong, J.; Shan, B.; Song, Z. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro. Breast Cancer Res. 2018, 20, 113. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Cai, L.; Ye, F.; Li, M.; Ma, L.; Geng, C.; Song, Z.; Liu, Y. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab. Medicine 2019, 98. [Google Scholar] [CrossRef] [PubMed]
- Meng, X.; Grötsch, B.; Luo, Y.; Knaup, K.X.; Wiesener, M.S.; Chen, X.X.; Jantsch, J.; Fillatreau, S.; Schett, G.; Bozec, A. Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat. Commun. 2018, 9, 1–17. [Google Scholar] [CrossRef]
- Sung, W.W.; Wang, Y.C.; Lin, P.L.; Cheng, Y.W.; Chen, C.Y.; Wu, T.C.; Lee, H. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin. Cancer Res. 2013, 19, 4092–4103. [Google Scholar] [CrossRef]
- Aras, S.; Raza Zaidi, M. TAMeless traitors: Macrophages in cancer progression and metastasis. Br. J. Cancer 2017, 117, 1583–1591. [Google Scholar] [CrossRef]
- Mohamed, H.T.; El-Husseiny, N.; El-Ghonaimy, E.A.; Ibrahim, S.A.; Bazzi, Z.A.; Cavallo-Medved, D.; Boffa, M.B.; El-Shinawi, M.; Mohamed, M.M. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. Curr. Probl. Cancer 2018, 42, 215–230. [Google Scholar] [CrossRef]
- Ouyang, W.; O’Garra, A. IL-10 Family Cytokines IL-10 and IL-22: From basic science to clinical translation. Immunity 2019, 50, 871–891. [Google Scholar] [CrossRef]
- Tausendschön, M.; Rehli, M.; Dehne, N.; Schmidl, C.; Döring, C.; Hansmann, M.L.; Brüne, B. Genome-wide identification of hypoxia-inducible factor-1 and -2 binding sites in hypoxic human macrophages alternatively activated by IL-10. Biochim. Biophys. Acta Gene Regul. Mech. 2015, 1849, 10–22. [Google Scholar] [CrossRef]
- Chen, Y.L.; Chen, P.M.; Lin, P.Y.; Hsiau, Y.T.; Chu, P.Y. ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients. Anticancer Res. 2016, 36, 2983–2988. [Google Scholar]
- Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45, W98–W102. [Google Scholar] [CrossRef] [PubMed]
- Nechuta, S.; Lu, W.; Zheng, Y.; Cai, H.; Bao, P.P.; Gu, K.; Zheng, W.; Shu, X.O. Comorbidities and breast cancer survival: A report from the Shanghai breast cancer survival study. Breast Cancer Res. Treat. 2013, 139, 227–235. [Google Scholar] [CrossRef] [PubMed]
- Tokunaga, E.; Nakashima, Y.; Yamashita, N.; Hisamatsu, Y.; Okada, S.; Akiyoshi, S.; Aishima, S.; Kitao, H.; Morita, M.; Maehara, Y. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 2014, 21, 341–349. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, N.; Ammar, A.; Storr, S.J.; Green, A.R.; Rakha, E.; Ellis, I.O.; Martin, S.G. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol. Immunother. 2018, 67, 537–549. [Google Scholar] [CrossRef] [PubMed]
- Moghimi, M.; Ahrar, H.; Karimi-Zarchi, M.; Aghili, K.; Salari, M.; Zare-Shehneh, M.; Neamatzadeh, H. Association of IL-10 rs1800871 and rs1800872 polymorphisms with breast cancer risk: A systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 2018, 19, 3353. [Google Scholar] [CrossRef]
- Arpino, G.; Weiss, H.; Lee, A.V.; Schiff, R.; De Placido, S.; Osborne, C.K.; Elledge, R.M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst. 2005, 97, 1254–1261. [Google Scholar] [CrossRef]
- Lee, S.G.; Kang, D.C.; DeSalle, R.; Sarkar, D.; Fisher, P.B. AEG-1/MTDH/LYRIC, the Beginning: Initial cloning, structure, expression profile, and regulation of expression. Adv. Cancer Res. 2013, 120, 1–38. [Google Scholar] [CrossRef]
- Sutherland, H.G.E.; Lam, Y.W.; Briers, S.; Lamond, A.I.; Bickmore, W.A. 3D3/lyric: A novel transmembrane protein of the endoplasmic reticulum and nuclear envelope, which is also present in the nucleolus. Exp. Cell Res. 2004, 294, 94–105. [Google Scholar] [CrossRef]
- Thirkettle, H.J.; Girling, J.; Warren, A.Y.; Mills, I.G.; Sahadevan, K.; Leung, H.; Hamdy, F.; Whitaker, H.C.; Neal, D.E. LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin. Cancer Res. 2009, 15, 3003–3013. [Google Scholar] [CrossRef]
- Dhiman, G.; Srivastava, N.; Goyal, M.; Rakha, E.; Lothion-Roy, J.; Mongan, N.P.; Miftakhova, R.R.; Khaiboullina, S.F.; Rizvanov, A.A.; Baranwal, M. Metadherin: A therapeutic target in multiple cancers. Front. Oncol. 2019, 9, 349. [Google Scholar] [CrossRef]
- Sheikhpour, E.; Noorbakhsh, P.; Foroughi, E.; Farahnak, S.; Nasiri, R.; Neamatzadeh, H. A survey on the role of interleukin-10 in breast cancer: A narrative. Rep. Biochem. Mol. Biol. 2018, 7, 30–37. [Google Scholar] [PubMed]
MTDH | IL-10 | ||||||
---|---|---|---|---|---|---|---|
Characteristics | No. | Low (n = 132) | High (n = 133) | p-Value | Low (n = 132) | High (n = 133) | p-Value |
Age | |||||||
<65 | 216 | 109 (51) | 107 (49) | 0.656 | 110 (51) | 106 (49) | 0.446 |
≥65 | 49 | 23 (47) | 26 (53) | 22 (45) | 27 (55) | ||
Stage | |||||||
I, II | 214 | 112 (52) | 102 (48) | 0.092 | 113 (53) | 101 (47) | 0.046 |
III, IV | 51 | 20 (39) | 31 (61) | 19 (39) | 32 (61) | ||
estrogen receptor (ER) | |||||||
Negative | 76 | 28 (37) | 48 (63) | 0.007 | 25 (33) | 51 (67) | <0.001 |
Positive | 189 | 104 (55) | 85 (45) | 107 (57) | 82 (43) | ||
progesterone receptor (PR) | |||||||
Negative | 106 | 43 (41) | 63 (59) | 0.014 | 42 (40) | 64 (60) | 0.007 |
Positive | 159 | 89 (56) | 70 (44) | 90 (57) | 69 (43) | ||
human epidermal growth factor receptor 2 (HER2) | |||||||
Negative | 180 | 93 (52) | 87 (48) | 0.379 | 90 (50) | 90 (50) | 0.929 |
Positive | 85 | 39 (46) | 46 (54) | 42 (49) | 43 (51) |
Overall Survival (OS) | ||||
---|---|---|---|---|
Characteristics | No. | Median Survival (Days) | 5-Year Survival (%) | Log-Rank |
Age | ||||
<65 | 216 | 1534 | 195 (91) | 0.024 |
≥65 | 49 | 1353 | 40 (82) | |
Stage | ||||
I, II | 214 | 1541 | 204 (95) | <0.001 |
III, IV | 51 | 981 | 32 (63) | |
ER | ||||
Negative | 76 | 1231 | 61 (80) | 0.002 |
Positive | 189 | 1569 | 175 (93) | |
PR | ||||
Negative | 106 | 1231 | 89 (84) | 0.018 |
Positive | 159 | 1624 | 147 (93) | |
HER2 | ||||
Negative | 180 | 1440 | 165 (92) | 0.076 |
Positive | 85 | 1492 | 71 (88) | |
MTDH | ||||
Low | 132 | 1805 | 124 (94) | 0.003 |
High | 133 | 1100 | 112 (84) | |
IL-10 | ||||
Low | 132 | 1734 | 123 (93) | 0.004 |
High | 133 | 1073 | 113 (86) | |
MTDH/IL-10 | ||||
Low/low | 95 | 1825 | 89 (94) | 0.004 |
Low/high | 37 | 1825 | 34 (92) | |
High/low | 37 | 1825 | 35 (95) | |
High/high | 96 | 1057 | 78 (81) |
Overall Survival (OS) | ||||
---|---|---|---|---|
Characteristics | HR | Unfavorable/Favorable | p-Value | 95% CI |
Age | 3.00 | ≥65/<65 | 0.154 | 0.66–13.34 |
Stage | 34.25 | III, IV/I, II | <0.001 | 8.25–142.29 |
MTDH/IL-10 | 8.00 | High, high/low, and low | 0.023 | 1.34–48.06 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chu, P.-Y.; Wang, S.-M.; Chen, P.-M.; Tang, F.-Y.; Chiang, E.-P.I. Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients. J. Clin. Med. 2020, 9, 3153. https://doi.org/10.3390/jcm9103153
Chu P-Y, Wang S-M, Chen P-M, Tang F-Y, Chiang E-PI. Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients. Journal of Clinical Medicine. 2020; 9(10):3153. https://doi.org/10.3390/jcm9103153
Chicago/Turabian StyleChu, Pei-Yi, Shin-Mae Wang, Po-Ming Chen, Feng-Yao Tang, and En-Pei Isabel Chiang. 2020. "Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients" Journal of Clinical Medicine 9, no. 10: 3153. https://doi.org/10.3390/jcm9103153
APA StyleChu, P.-Y., Wang, S.-M., Chen, P.-M., Tang, F.-Y., & Chiang, E.-P. I. (2020). Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients. Journal of Clinical Medicine, 9(10), 3153. https://doi.org/10.3390/jcm9103153